Penicillin G acylase containing one or a plurality of point mutation

A technology of penicillin and acylase, which is applied in the field of penicillin G acylase and its application in the production of β-lactam antibiotics, can solve the problems of reduced synthetic activity, many by-products, and low synthetic activity, and achieve the goal of producing The effect of increasing the amount of enzyme, reducing the cost and saving raw materials

Active Publication Date: 2013-05-01
CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition, the international patent application WO96 / 05318 changes the specificity and synthesis / hydrolysis ratio of PGA by mutating one or more amino acids of the substrate binding site; The mutation of the β56 or β177 amino acid, especially the mutant βF 24A, has a significant increase in the production of penicillins and cephalosporins; while in WO03 / 055998, although the mutants αR145L, αR145C, and αR145K have higher synthesis / hydrolysis ratio, but the synthetic activity is greatly reduced, and the mutant of BmPGA reported by Chinese patent CN101177688 also shows similar results
[0007] Although researchers have isolated, purified, cloned and expressed many naturally occurring PGAs and modified them, these PGAs are still unsatisfactory in many aspects, such as inefficient maturation into active enzymes, low synthetic activity or synthesis / hydrolysis (S / H) The ratio is low, and the by-products generated are many, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Penicillin G acylase containing one or a plurality of point mutation
  • Penicillin G acylase containing one or a plurality of point mutation
  • Penicillin G acylase containing one or a plurality of point mutation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1 Construction, prokaryotic expression and functional identification of the gene encoding the penicillin G acylase mutant

[0075] 1. Primer Design

[0076] will be on GeneBank E. coli The penicillin G acylase derived from ATCC11105 is a gene sequence, which is synthesized from the whole gene and primers are designed.

[0077] The primer sequence used for cloning in the prokaryotic expression vector pET-24a is:

[0078] Primer P1: 5'-ACCG CATATG GAGCAGCTTAGTTCAGAAATC-3' (the underlined base is the NdeI recognition site);

[0079] Primer P2: 5'-ACCG AAGCTT ATCTCTGGACGTGAAGGAC -3' (the underlined base is the HindIII recognition site); the penicillin G acylase gene sequence amplified by the pair of primers is shown in SEQ ID NO.2, and the penicillin G acylase protein encoded by it has Amino acid sequence shown in SEQ ID NO.1.

[0080] The primer sequences for the expression vector pAO815 clone in yeast are:

[0081] Primer P3: 5'-ACCG GAATTC GAGCAGCTTA...

Embodiment 2

[0139] Example 2 Eukaryotic expression and functional identification of penicillin G acylase mutant

[0140] Four copies of yeast expression vectors of mutants 20, 21, 22, and 24 were respectively constructed and transformed into Pichia pastoris cells. Mutant 20 was used as an illustration below, and the construction methods of other mutants were the same.

[0141] 1. Eukaryotic expression of penicillin G acylase mutants

[0142] The PGA gene of mutant 20 was introduced into the yeast expression vector pAO815 (invitrogen company) using the EcoRI restriction sites carried by primers P3 and P4, and transformed into E. coli In the TOP10, the E. coli TOP10 (pAO815-PGA) was cultured overnight in LB liquid medium at 37°C with shaking at 160 rpm, and the recombinant plasmid was extracted. The recombinant plasmid pAO815-PGA was linearized with SalI.

[0143] The linearized recombinant plasmid pAO815-PGA was transformed into yeast cells.

[0144] Preparation of Pichia pastoris GS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a new penicillin G acylase mutant, nucleic acid for encoding the mutant, a related expression vector, host cells, and a use of the mutant in amoxicillin synthesis.

Description

technical field [0001] The invention relates to the field of medicine production, in particular to the production of beta-lactam antibiotics and enzymes used for production thereof, more specifically to penicillin G acylase and its application in the production of beta-lactam antibiotics. Background technique [0002] β-lactam antibiotics are the most important class of antibiotics in clinical application (including penicillins and cephalosporins, etc.), the penicillane or cephem contained in their molecules can destroy the cell wall of bacteria and reproduce in bacterial cells play a bactericidal role. Naturally occurring β-lactam antibiotics have disadvantages such as narrow antibacterial spectrum, acid resistance, easy drug resistance, and easy allergic reactions. These shortcomings have prompted the development of semi-synthetic penicillins and semi-synthetic cephalosporins. [0003] Penicillin G acylase (penicillin G acylase, PGA, EC 3.5.1.11)) can hydrolyze penicillin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/84C12N15/55C12N15/63C12N1/15C12N1/19C12N1/21C12N5/10C12P37/04
CPCY02P20/52
Inventor 余允东王晓霞祝俊杨晓鹏吴清云吴会广马春艳
Owner CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products